Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Neurology - 13 Dec 2005

Martignoni E, Cosentino M, Ferrari M, Porta G, Mattarucchi E, Marino F, Lecchini S, Nappi G

Abstract excerpt

The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Catechols
Share to Chemical and Drug Induced Liver Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronates

Share to Liver Diseases

Share to Nitriles

Share to Nitrophenols

Share to UDP-Glucuronosyltransferase 1A9

Source

Identifiers

PMID: 16344532
DOI: 10.1212/01.wnl.0000187066.81162.70

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.PMID 16344532Read ↗

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.Semantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.Semantic proximity Read ↗

Liver enzyme abnormalities in Parkinson's disease.Semantic proximity Read ↗

High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease.Semantic proximity Read ↗

The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis.Semantic proximity Read ↗

Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase.Semantic proximity Read ↗

Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?Semantic proximity Read ↗

A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.